Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses

Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are a mainstay treatment for hormone receptor-positive breast cancer. While their principal mechanism is inhibition of cancer cell proliferation, preclinical and clinical evidence suggests that CDK4/6i can al...

Full description

Bibliographic Details
Main Authors: Roman Uzhachenko, Sangeetha M Reddy, Ann Richmond, Amrendra Kumar, Vijay Ramani, Vijaya Bharti, Daniel de Lima Bellan, Nabil Saleh, Chengli Shen, Carlos Arteaga, Anna Vilgelm
Format: Article
Language:English
Published: BMJ Publishing Group 2023-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/5/e006019.full

Internet

https://jitc.bmj.com/content/11/5/e006019.full

Similar Items